MTD Rapid Test Cassette (Whole Blood/Serum/Plasma)

Package Insert

A rapid test for the qualitative detection of Methadone in human whole blood or serum or plasma. For medical and other professional in vitro diagnostic use only.

INTENDED USE

The MTD Rapid Test Cassette (whole blood/serum/plasma) is a lateral flow chromatographic immunoassay for the detection of Methadone in whole blood or serum or plasma at a cut-off concentration of 40ng/ml. This test will detect other related compounds, please refer to the analytical Specificity table in this package insert.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

ISUMMARY

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to beprescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists

(PRINCIPLE)

The MTD Rapid Test Cassette (whole blood/serum/plasma) is an immunoassay based on the principle of competitive binding. Drugs that may be present in the whole blood/serum/plasma specimen compete against the drug conjugate for binding sites on the antibody.

During testing, a whole blood/serum/plasma specimen migrates upward by capillary action. Methadone, if present in the whole blood/serum/plasma specimen below the cut-off level, will not saturate the binding sites of the antibody in the test. The antibody coated particles will then be captured by immobilized Methadone-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Methadone level exceeds the cut-off level because it will saturate all the binding sites of anti-Methadone antibodies.

A drug-positive whole blood/serum/plasma specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative whole blood/serum/plasma specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred. [REAGENTS]

The test contains mouse monoclonal anti-Methadoneantibody coupled particles and Methadone-protein conjugate. A goat antibody is employed in the control line system.

[PRECAUTIONS]

- · For professional in vitro diagnostic use only. Do not use after the expiration date.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Do not use test if pouch is damaged
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens
- · Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- The used test should be discarded according to local regulations.
- Humidity and temperature can adversely affect results.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

- · The MTD Rapid Test Cassette can be performed using whole blood (from venipuncture or fingerstick)/serum/plasma
- To collect Fingerstick Whole Blood specimens:
- · Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.
- · Massage the hand without touching the puncture site by rubbing down the hand towards the
- fingertip of the middle or ring finger
- Puncture the skin with a sterile lancet. Wipe away the first sign of blood.
- Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture
- Add the Fingerstick Whole Blood specimen to the test by using <u>a capillary tube</u>
- Touch the end of the capillary tube to the blood until filled to approximately 40 μl. Avoid air hubbles
- · Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the whole blood to the specimen area of the test cassette.
- Testing should be performed immediately after the specimens have been collected. Do not leave the specimens at room temperature for prolonged periods. For long term storage, specimens should be kept below -20°C. Whole blood/serum/plasma collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood or serum or plasma specimens. Whole blood/serum/plasma collected by fingerstick should be tested immediately
- · Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

[MATERIALS]

Materials Provided						
 Test cassettes 	 Droppers 	 Buffer 	 Package insert 			
	Materials Required But Not Provided					
 Specimen collection conta 	iners		 Centrifuge 			
 lancets (for fingerstick whole blood only) 			Timer			
I have a station of a second large state of a second	and diaman franch with the stars	والمحاط والمحاوين بالمتقوم	h h			


Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

[DIRECTIONS FOR USE]

Allow the test, specimen, buffer and/or controls to reach room temperature (15-30°C) prior to testina.

For serum or plasma specimen:

- 1. Bring the pouch to room temperature (15-30°C) before opening it. Remove the cassette from the sealed pouch and use it within one hour.
- 2. Place the cassette on a clean and level surface. Hold the dropper vertically and transfer 1 full drop of serum or plasma (approximately 40ul), then add 2 drops of buffer (approximately 80 µl) to the specimen well of the cassette, and then start the timer. Avoid trapping air bubbles in the specimen well. See illustration below.
- 3. Wait for the colored line(s) to appear. Read the result at 5 minutes. Do not interpret the result after 10 minutes




For whole blood specimen:

1. Bring the pouch to room temperature before opening it. Remove the test cassette from the sealed pouch and use it as soon as possible

- 2. Place the cassette on a clean and level surface
- For Venipuncture Whole Blood specimen:
- Hold the dropper vertically and transfer 1 drop of whole blood(approximately 40µl) to the specimen well, then add 2 drops of buffer (approximately 80 µl), and start the timer. See illustration below
- For Fingerstick Whole Blood specimen:
- To use a capillary tube: Fill the capillary tube and transfer approximately 40µl of fingerstick whole blood specimen to the specimen area of test cassette, then add 2 drops of buffer (approximately 80 µl) and start the timer. See illustration below.

3.Wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Methadone concentration is below the detectable cut-off level

*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the Methadone concentration exceeds the detectable cut-off level.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL 1

A procedural control is included in the test. A colored line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit: however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance

[LIMITATIONS]

- 1. The MTD Rapid Test Cassette (whole blood/serum/plasma) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/ mass spectrometry (GC/MS) is the preferred confirmatory method.
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the whole blood or serum or plasma specimen may cause erroneous results.
- 3. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in whole blood or serum or plasma.
- 4. A negative result may not necessarily indicate drug-free whole blood/serum/plasma. Negative results can be obtained when drug is present but below the cut-off level of the test.
- Test does not distinguish between drugs of abuse and certain medications.

EXPECTED VALUES

This negative result indicates that the Methadone concentration is below the detectable level of 40ng/ml. Positive result means the concentration of Methadoneis above the level of 40ng/ml. The MTD Rapid Test Cassette has a sensitivity of 40ng/ml (PERFORMANCE CHARACTERISTICS)

Accuracy

A side-by-side comparison was conducted using The MTD Rapid Test Cassette and GC/MS at the cut-off of 40ng/ml. Testing was performed on 90 clinical specimens previously collected from subjects present for Drug Screen Testing. The following results were tabulated: Clinic Result of Whole Blood

Method		GC	/MS	Total Results		
MTD Banid Test	Results	Positive	Negative	Total Results		
MTD Rapid Test Cassette	Positive	19	2	21		
Casselle	Negative	1	68	69		
Total Results		20	70	90		
% Agreement		95.0%	97.1%	96.7%		
Clinic Result of Serum or Plasma						
Method		GC	/MS	Total Beaulta		
	Results	Positive	/MS Negative	Total Results		
MTD Rapid Test	Results Positive			Total Results 21		
		Positive	Negative			
MTD Rapid Test	Positive Negative	Positive	Negative 2	21		
MTD Rapid Test Cassette	Positive Negative ts	Positive 19 1	Negative 2 68	21 69		

Analytical Sensitivity

A drug-free whole blood/serum/plasma pool was spiked with MTD at the following concentrations of +50%cutoff and 3xcutoff. The data are summarized below:

For whole blood

MTD Concentration	Percent of Cut-off		Visual Result			
(ng/ml)	Percent of Cut-off	n	Negative	Positive		
0	0	30	30	0		
20	-50%	30	30	0		
40	Cut-off	30	15	15		
60	+50%	30	0	30		
120	3X	30	0	30		
For serum or plasma:						

Me

Do

MTD Concentration	Percent of Cut-off	n	Visual Result			
(ng/ml)	Fercent of Cut-on		Negative	Positive		
0	0	30	30	0		
20	-50%	30	30	0		
40	Cut-off	30	15	15		
60	+50%	30	0	30		
120	3X	30	0 30			
Analytical Specificity						

The following table lists compounds that are positively detected in whole blood/serum/plasmaby The MTD Ranid Test Co

D Rapid Test Casselle (whole blood/seru	m/piasma) at 5 minutes.
Compound	Concentration (ng/ml)
ethadone	40
oxylamine	13,000
,	Provision

A study was conducted at three hospitals by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing no Methadone, and 50% Methadone above and below the 40ng/ml cut-off was provided to each site. The following results were tabulated

MTD Concentration	n	Site A		Site A Site B		Site C	
(ng/ml)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
20	10	8	2	9	1	9	1
60	10	1	9	1	9	2	8
Cross-Reactivity							

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free whole blood/serum/plasma or Methadone positive whole blood/serum/plasma. The following compounds show no cross-reactivity when tested with The MTD Rapid Test Cassette (whole blood/serum/plasma) at a concentration of 100 µg/ml

Non Cross-Reacting Compounds							
Acetaminophen	Diazepam	Maprotiline	-Phenylethylamine				
Acetophenetidin	Diclofenac	Meperidine	Phenylpropanolamine				
N-Acetylprocainamide	Diflunisal	Meprobamate	Prednisolone				
Acetylsalicylic acid	Digoxin	Methamphetamine	Prednisone				
Aminopyrine	Diphenhydramine	Methoxyphenamine	Procaine				
Amitryptyline	EDDP	(±) - 3,4-Methylenedioxy-	Promazine				
Amobarbital	EMDP	amphetamine	Promethazine				
Amoxicillin	Ecgonine hydrochloride	(±) - 3,4-Methylenedioxymeth-	D,I-Propranolol				
Ampicillin	Ecgoninemethylester	Amphetamine	D-Propoxyphene				
I-Ascorbic acid	(-) -ψ-Ephedrine	Morphine-3-	D-Pseudoephedrine				
D,I-Amphetamine	[1R,2S] (-) Ephedrine	β-D glucuronide	Quinacrine				
sulfate							
Apomorphine	I - Epinephrine	Morphine Sulfate	Quinidine				
Aspartame	Erythromycin -Estradiol	Nalidixic acid	Quinine				
Atropine Benzilic acid		Naloxone	Ranitidine				
Benzoic acid	Estrone-3-sulfate Ethyl-p-aminobenzoate	Naltrexone Naproxen	Salicylic acid Secobarbital				
Benzoylecgonine	Fenoprofen	Niacinamide	Serotonin				
Benzphetamine	Furosemide	Nifedipine	Sulfamethazine				
Bilirubin	Gentisic acid	Norcodein	Sulindac				
(±) - Brompheniramine	Hemoglobin	Norethindrone	Temazepam				
Caffeine	Hydralazine	D-Norpropoxyphene	Tetracycline				
Cannabidiol	Hydrochlorothiazide	Noscapine	Tetrahydrocortisone,				
Cannabinol	Hydrocodone	D,I-Octopamine	3-Acetate				
Chloralhydrate	Hydrocortisone	Oxalic acid	Tetrahydrocortisone				
Chloramphenicol	O-Hydroxyhippuric acid	Oxazepam	3-(-D-glucuronide)				
Chlorothiazide	p-Hydroxyamphetamine		Tetrahydrozoline				

(±) - Chlorpheniramine	p-Hydroxy-	Oxycodone	Thebaine
Chlorpromazine	methamphetamine	Oxymetazoline	Thiamine
Chlorquine	3-Hydroxytyramine	Papaverine	Thioridazine
Cholesterol	Ibuprofen	Penicillin-G	D,I-Tyrosine
Clomipramine	Imipramine	Pentazocine hydrochloride	Tolbutamide
Clonidine	Iproniazid	Pentobarbital	Triamterene
Cocaethylene	(±) - Isoproterenol	Perphenazine	Trifluoperazine
Cocaine hydrochloride	Isoxsuprine	Phencyclidine	Trimethoprim
Codeine	Ketamine	Phenelzine	Trimipramine
Cortisone	Ketoprofen	Phenobarbital	Tryptamine
(-) Cotinine	labetalol	Phentermine	D,I-Tryptophan
		• • •	••••

(-) Cotinine labetalol Phentermine D,I-I ryptophan Interfering Substances
 The MTD Rapid Test Cassette (whole blood/serum/plasma) has been tested for possible interference from visibly hemolyzed and lipernic specimens. In addition, no interference was observed in specimens containing up to 100 mg/dl hemoglobin;up to 100 mg/dl bilirubin; and up to 200 mg/dlhuman serum albumin.
 [BIBLIOGRAPHY]
 1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735
 2. Baselt RC. <u>Disposition of Toxic Drugs and Chemicals in Man</u>_2nd Ed. Biomedical Publ., Davis, CA.

145319701 Number: Effective date: 2017-06-22